HOUSTON, Texas — Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells (also referred to as Multi-Antigen Recognizing T cells, or MAR-T cells, by Marker), a technology developed at Baylor College of Medicine for the treatment of hematologic and...
treatment News
Houston, TX – Hepatoblastoma (HB) is the most common liver cancer in children. Researchers and physicians in the field are concerned because in the last decade HB has been rising rapidly worldwide and has seen the most rapid increase among all pediatric solid tumors. A team led by researchers at...
SOUTH SAN FRANCISCO, Calif. — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma. “Receiving Fast...
Braunschweig, Germany – A new research paper was published in Oncotarget’s Volume 14 on December 1, 2023, entitled, “Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.” In multiple myeloma patients, high levels of soluble B-cell maturation antigen (sBCMA) can limit...
Preclinical research demonstrates that a single administration of BE-102 provides continuous secretion of active alkaline phosphatase (ALP) in vivo out to 6 months No safety findings observed in long-term pharmacology studies Data presented at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting CAMBRIDGE, Mass. — Be Biopharma,...
LONDON, UK and CAMBRIDGE, Mass. — Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced a 12-month safety and efficacy update from its Phase 2 DAWN trial...
LONDON, UK and CAMBRIDGE, Mass. — Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced new results from two Phase 2 trials, SKYLINE and DAWN, evaluating the...
CAMBRIDGE, Mass. — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced updated safety and efficacy data from the ongoing Phase 1/2 trial of BEAM-302 and the selection of 60 mg as the optimal biological dose to advance into pivotal development to support...
Authorisation is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BASEL, Switzerland & CAMBRIDGE, Mass. – BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for BRUKINSA® (zanubrutinib) in Great Britain, for the treatment of eligible...
CAMBRIDGE, Mass. & BEIJING – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® (zanubrutinib) has received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have...